IntroductionPostpartum depression (PPD) is a common perinatal condition with significant consequences for the patient, child, and family. The efficacy and safety of zuranolone, an oral, once-daily, 14-day treatment for PPD in adults, was assessed in the pivotal SKYLARK and ROBIN studies. The Hamilton Depression Rating Scale 17 (HAMD-17) and Montgomery-Asberg Depression Rating Scale (MADRS) were the primary and a secondary endpoint, respectively. Both studies enrolled participants with a HAMD-17 score ≥ 26 (indicative of severe depressive symptoms). However, the efficacy and safety of zuranolone in patients with moderate PPD remains uncertain.
Disclosure of InterestK. Deligiannidis Consultant of: GH Research, Sage Therapeutics, Inc., Brii Biosciences, Inc., Lipocine, Gerbera Therapeutics, Reunion Neuroscience, Neurocentria, Brainify, and NextSense, J. A. Ramos-Quiroga Grant / Research support from: Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Exeltis, Idorsia, Casen-Recordati, Takeda, Neuraxpharm, Oryzon, Roche, Probitas, Rubió, and Johnson & Johnson., Consultant of: Biogen, Idorsia, Casen-Recordati, Johnson & Johnson, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, Lilly, BMS, Medice, Rubió, Uriach, Technofarma, and Raffo, Speakers bureau of: Biogen, Idorsia, Casen-Recordati, Johnson & Johnson, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, Lilly, BMS, Medice, Rubió, Uriach, Technofarma, and Raffo, B. Nair: None Declared, A. Artemyeva Employee of: Biogen Inc. and may hold stock, K. LaGuerre Employee of: Biogen Inc. and may hold stock, H. Finnigan Employee of: Biogen Inc. and may hold stock, F. Forrestal Employee of: Biogen Inc. and may hold stock, J. Jung Employee of: Biogen Inc. and may hold stock, V. Nguyen Employee of: Biogen Inc. and may hold stock, M. Adams Employee of: Biogen Inc. and may hold stock